<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04354090</url>
  </required_header>
  <id_info>
    <org_study_id>DFBT-JY09-101a</org_study_id>
    <nct_id>NCT04354090</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09</brief_title>
  <official_title>Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09, a Long-acting Glucagon-like Peptide-1 Mimetic, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Dongfang Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Dongfang Biotech Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      JY09 is a glucagon-like peptide-1 (GLP-1) mimetic generated by genetic fusion of a Exendin-4
      dimer to human immunoglobulin Fc.

      In this Double-blind, randomized, placebo-controlled trial, 41 healthy subjects received
      placebo or escalating doses of JY09 on day 1 in the first cohort, and on days 1 and 22 in the
      following sequential cohort 2-4, and on days 1, 15, and 30 in the cohort 5: cohort 1: 0.3 mg;
      cohort 2: 0.3 + 0.7 mg; cohort 3: 0.7+1.5 mg; cohort 4: 0.7+3.0 mg; and cohort 5: 0.7 + 1.5 +
      6.0 mg. The primary endpoints were the incidence of adverse events and serious adverse events
      related to JY09. Secondary endpoints included pharmacodynamics and pharmacokinetics
      parameters, as well as anti-JY09 antibody incidence and titers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2018</start_date>
  <completion_date type="Actual">June 22, 2019</completion_date>
  <primary_completion_date type="Actual">December 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events and serious adverse events related to JY09</measure>
    <time_frame>Up to day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics parameters: Cmax</measure>
    <time_frame>Up To day 42</time_frame>
    <description>Average Cmax of each dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics parameters: AUC</measure>
    <time_frame>Up to day 42</time_frame>
    <description>Average AUC follewing single dose of each doase level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics parameters: Half-life</measure>
    <time_frame>Up to day 42</time_frame>
    <description>Average Half-life of each dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics parameters</measure>
    <time_frame>Day 5</time_frame>
    <description>OGTT test was conducter predose and 5 days after the target dose in each cohorts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Up To day 42</time_frame>
    <description>Anti-JY09 antibody incidence at each dose level</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Cohort 0.3-mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects received 0.3 mg placebo or JY09 on day 1 in this cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 0.7-mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects received 0.3 mg placebo or JY09 on days 1, and 0.7 mg placebo or JY09 on days 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1.5-mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.5 mg placebo or JY09 on days 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3.0-mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 3.0 mg placebo or JY09 on days 22</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6.0-mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible subjects received 0.7 mg placebo or JY09 on days 1, and 1.0 mg placebo or JY09 on days 15, and 6.0 mg placebo or JY09 on days 30</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JY09</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Cohort 0.3-mg</arm_group_label>
    <arm_group_label>Cohort 0.7-mg</arm_group_label>
    <arm_group_label>Cohort 1.5-mg</arm_group_label>
    <arm_group_label>Cohort 3.0-mg</arm_group_label>
    <arm_group_label>Cohort 6.0-mg</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  Male's mass is ≥50 kg, female's mass is ≥45 kg, have a body mass index between 18 and
             26 kg/m^2

          -  Subjects or their legal representative signed informed consent

          -  agree to use instruments of contraception from the time of the first dose until 6
             months after the last dose of investigational drug, avoid pregnancy make yourself or
             your mate

          -  Able to keep good communication with investigator and comply with the requirements of
             the clinical trials

        Exclusion Criteria:

          -  Smokers,quitting time less than 3 months , or can't quit smoking during the trial

          -  Use of any prescription drugs within 4 weeks prior dosing, or over-the-counter
             medication (vitamins, herbal supplements, dietary supplements) within 2 weeks prior to
             dosing,or being treated for a direct lower gastrointestinal or using steroids

          -  Participation in any clinical investigation within 3 months prior to dosing

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to first dosing

          -  Significant illness within 2 weeks prior to dosing,and investigator judge doesn't fit
             to participate in this trial

          -  A history of clinical significance of abnormal ECG

          -  A history of diabetes, hyperuricemia and hyperlipidemia

          -  A history of acute or chronic bronchial spasms

          -  Have clinical significant gastrointestinal diseases

          -  Have serious, progressive, or uncontrolled organ or system diseases

          -  Abuse of drug or alcohol within 12 months before first dosing

          -  People who are pregnant, nursing mothers, or in the near future plan to be pregnant,or
             show pregnancy test positive before into group

          -  Subjects who, in the opinion of the investigator, are in any way unsuitable to
             participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 16, 2020</last_update_submitted>
  <last_update_submitted_qc>April 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

